Details for New Drug Application (NDA): 205382
✉ Email this page to a colleague
NDA 205382 describes INCRUSE ELLIPTA, which is a drug marketed by Glaxo Grp England and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the INCRUSE ELLIPTA profile page.
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.
Summary for 205382
| Tradename: | INCRUSE ELLIPTA |
| Applicant: | Glaxo Grp England |
| Ingredient: | umeclidinium bromide |
| Patents: | 7 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 205382
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 205382
| Mechanism of Action | Cholinergic Antagonists |
Suppliers and Packaging for NDA: 205382
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382 | NDA | GlaxoSmithKline LLC | 0173-0873 | 0173-0873-06 | 1 TRAY in 1 CARTON (0173-0873-06) / 1 INHALER in 1 TRAY / 7 AEROSOL, POWDER in 1 INHALER |
| INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382 | NDA | GlaxoSmithKline LLC | 0173-0873 | 0173-0873-10 | 1 TRAY in 1 CARTON (0173-0873-10) / 1 INHALER in 1 TRAY / 30 AEROSOL, POWDER in 1 INHALER |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INHALATION | Strength | EQ 0.0625MG BASE/INH | ||||
| Approval Date: | Apr 30, 2014 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Dec 18, 2027 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | ⤷ Sign Up | Patent Expiration: | Apr 27, 2025 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | ⤷ Sign Up | Patent Expiration: | Jul 27, 2025 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA. | ||||||||
Expired US Patents for NDA 205382
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
